Earlier this spring, a Pfizer-funded
survey reported that 54%
of New Zealanders knew little about antiviral
treatments for Covid-19.
The SMC asked experts about
access to Covid-19 antiviral medicines and what we know
about the risks of reinfection.
Dr Jin Russell,
Developmental Paediatrician, Starship Children’s Hospital
and PhD Student, School of Population Health, University of
Auckland, comments:
How accessible are Covid-19
antivirals in NZ?
“There seem to be multiple
barriers to accessing antiviral medications for Covid-19,
and I’m concerned that we may have inequities in health
outcomes as a result.
“The first issue is a lack of
awareness – many members of the public don’t seem to be
aware of their eligibility for antivirals should they have
an infection, as found in an online
survey of New Zealanders.
“The second
issue is access to antivirals. Many people have reached out
to me to tell me how they struggled to access antivirals,
despite feeling they met eligibility criteria. Some have
said they contacted several pharmacies that were listed on
Healthpoint as dispensing pharmacies, only to find that
these pharmacies were not dispensing antivirals. For
instance, my own local pharmacy is listed as a dispensing
pharmacy on Healthpoint, yet the pharmacists there recently
told me they aren’t dispensing – they stopped after
calculating that it would take them 45 minutes to dispense a
single course of antivirals. Getting a GP appointment can be
challenging due to shortages, leading to delays outside of
the five-day window for antiviral treatment. A GP has told
me that her patients have received conflicting information
on their eligibility for antivirals from
Healthline.
“Some previously fit and well people
have told me that they experienced prolonged fatigue for
several months – long Covid symptoms – after their first
infection, and they wish that there was consideration of
previous long Covid in the eligibility criteria. This is an
emerging area of research.
“I’m concerned that we
have several hundred people in hospital with Covid-19 and
that a significant number of Covid-19 related deaths are
being reported each week during the current wave. I wonder
what proportion of these cases were eligible for antivirals
and did not receive them.”
How important is access
to Covid-19 antivirals in NZ?
“It’s important for
the public to know that anyone 65 years of age or over, and
Māori and Pacific and unvaccinated persons 50 years of age
or over, and people with three or more high-risk medical
conditions are eligible for antivirals.
“Antivirals
have been found to be highly effective in reducing the risk
of hospitalisation and death due to Covid-19 according to a
recent
paper published in The New England
Journal of Medicine, so it is vital that we reduce
barriers to accessing these.”
No conflicts of
interest.
Dr Rawiri Keenan (Te Atiawa/Taranaki),
Adjunct Senior Fellow, Medical Research Centre, Te Huataki,
University of Waikato; Senior Research Fellow, Dept of
Primary Care and General Practice, University of Otago
Wellington, comments:
How important is access to
Covid-19 antivirals in NZ?
“Increasing access to
antivirals was important, but avoiding infection and
reinfection in the first place is still the key thing that
we can be doing right now. The Pfizer
survey results need to be taken with a grain of
salt because access has widened since then, and also it is a
little self-serving for them to push more uptake of their
medication. A medication that helps reduce the severe
effects of the illness is helpful for keeping people alive
and our hospitalisation rate down. But so far, evidence
seems to suggest mild-to-moderate cases of COVID-19 are
still at risk of Long Covid – and we aren’t sure if
antivirals help with this.
“From a public health
perspective, increasing the use of masks – even now as we
climb towards 10,000 cases a day – would help. I’m not a
modeller but I’m sure in many settings, stringent mask use
would be more effective at reducing hospitalisations than
antivirals once already infected. Sadly, the only certainty
of this Christmas/New Year is that many, many people will be
in hospital with COVID-19, many more at home isolating and
unwell, and a number will die. As has been the case this
entire pandemic, this will affect Māori and Pacifica people
more.”
How accessible are Covid-19 antivirals in
NZ?
“A concern with the rising number of Covid cases
as we approach Christmas is that the ability to get these
antivirals, where clinically appropriate, will reduce. While
many pharmacies usually stay open over weekends, during
these summer holidays on statutory holiday days they will
join general practice teams in largely being
closed.
“We were sold a ‘summer of certainty’
but unfortunately, GP teams – as with most other parts of
the health system – are needing to pause usual care to
meet the demands of COVID-19. There is, as far as I am
aware, no plan for widening GP or pharmacy access to
antivirals than usual over the prolonged statutory holiday
periods, which will leave many people who could be eligible
with limited access (they need to be started within five
days of illness onset).
“While primary care teams
(GP, nurses, pharmacy etc) are funded for assessments and
prescription, etc. of antivirals, there has been no let up
or catch up from previous waves, leaving the majority
planning on closing over the Christmas period as usual to
give staff a well-earned break. Though I’m sure for many,
especially in rural areas, the on-call work will be more
than the usual summer holiday-goers due to COVID-19. Sadly,
with the state of the workforce, even if funding was made
available to remain open/available, I’m not sure many GP
teams would have the staff.
“Antivirals are great,
the widened access to include more Māori and Pacifica in
antivirals and boosters is great too – but with our
out-of-date vaccines (not bivalent and many, many people are
more than one-year since their booster) and the lack of
basic public health measures for an airborne virus, we are
relying too much on a treatment for an illness, when we know
for everything from infection to diabetes – prevention is
better than cure.”
Conflict of interest
statement: “I am a team member for projects with Victoria
University of Wellington and University of Otago funded by
the Ministry of Health evaluating the Covid vaccine
roll-out. I am a Locum GP; Member of Te Rōpū Whakakaupapa
Uruta; Member of Te Aho o te Kahu Clinical Assembly and
Member of Health Quality and Safety Commission Patient
Experience of Care Governance Group.”
Dr Anna
Brooks, Cellular immunologist, Senior Lecturer, and Senior
Research Fellow, Maurice Wilkins Centre, University of
Auckland, comments:
What’s the latest evidence on
the health risks of reinfection?
“Emerging evidence
is indicating that the risk of long-term health harms, not
just Long Covid, increase with each subsequent reinfection.
Our vaccine- and/or infection-induced immune system
protection is not enough to prevent infection or protect
against all health risks. This is especially important given
the Omicron variants and subvariants that continue to evolve
to evade our immune defences.
“First and foremost,
prevention is always better than requiring treatment. No
infection is safe, and given our vaccine- and/or
infection-induced immunity only provides limited protection
against illness and lasting health harms, each exposure
event comes with a risk. Clear messaging about reducing
harms needs to continue, including the importance of high
quality masks and ventilation, encouraging testing before
high risk events, and isolating when unwell with any
symptoms.
“Therefore, it is important that we have
both clear messaging surrounding the ongoing risks to our
health from infection, as well as better access to
antivirals when appropriate. A
study currently under review conducted by a
highly reputable group, revealed a 26% reduction in Long
Covid symptoms for people who took Paxlovid, which is
encouraging.”
What do these risks imply for NZ’s
pandemic response?
“As data is showing that each
infection increases health harms and antivirals can reduce
the risk of these harms, it would be good to see access to
antivirals extended, especially to those already living with
Long Covid.
“People living with post-viral illnesses
(Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
and Long Covid) are calling for better access to antivirals,
given all health protections have been dropped, and access
to a second booster doesn’t extend to this ‘at risk’
group. Research efforts are underway to develop tests to
clinically define immune dysfunction more conclusively in
these groups. But can we really afford to keep ‘waiting
for more data’ when there are tools available to reduce
health harms?”
No conflicts of interest
declared.
Dr Amanda Kvalsvig, epidemiologist,
Department of Public Health, University of Otago Wellington,
comments:
What does the latest evidence suggest about
the risks of reinfection?
“The research literature
continues to show substantial and growing evidence about the
health risks from ongoing waves of Covid-19 infection, with
further impacts in turn on the safe functioning of health,
education, and other systems. So the big question is why the
New Zealand public isn’t being advised every day that
it’s in their best interests to avoid getting infected and
reinfected.”
“Recent research: The impact of
Covid-19 reinfections is challenging to study because
reinfections are undercounted in population data. But a
recent study of the US
Veterans Affairs cohort published in Nature
Medicine has provided some very high-quality evidence.
This study showed that people with a higher number of
infections had a significantly higher risk of new and
serious health conditions, compared with those who had
experienced only one infection. The authors were careful to
address important sources of confounding in their analysis,
so this is a high-quality paper. The study appropriately
didn’t test whether subsequent infections had milder or
more serious early symptoms than the first – the amount of
data collection needed to answer that question would have
been huge and it would have added no practical, actionable
information: we already know that serious health effects can
follow a mild early infection.”
What do these risks
imply for NZ’s pandemic response?
“The need for
action: The refrain we’ve heard so many times during the
pandemic is that ‘more research is needed’ before the
Government can act. But as our case numbers rise again, we
need to question exactly what information is being awaited
before the decision is made to step up and protect the
public. The US Veterans Study referred to above had more
participants than the entire population of Aotearoa New
Zealand. That is a lot of data points. Even if the results
were only applied to New Zealanders from a similar
demographic, the population health consequences here would
be highly concerning. The combined evidence from this study
and thousands of others indicates that every day spent
waiting to act is knowingly exposing more people to risk
from these serious and life-altering
outcomes.”
“The only sensible way to deal with
this level of credible risk is to take a precautionary
approach. We have plenty of protections that can keep people
safe while going about their daily lives. Highly effective
ways to keep us connected and safe include providing clean
indoor air in all public settings including schools,
requiring and providing high-quality masks on public
transport, requiring rapid antigen testing for large events
and when exiting isolation; providing protected sick leave
for all workers, and many more. It’s frustrating to see
that New Zealand is currently under-using all of these
well-established and cost-effective protections in the face
of very clear evidence of risk.”
No conflicts of
interest declared.
Dr Emily Harvey, Co-lead of the
Contagion Network modelling programme, COVID-19 Modelling
Aotearoa, comments:
What is the outlook from here,
with reinfections on the rise?
“Right now in
Aotearoa NZ, our gradual waning of immunity from past
infection and vaccination is being helped along by new
variants that are better at evading our immunity and are
causing a new wave of infections. From the modelling, we
expect to see cases and infections rising over the next
couple of weeks, and peaking late in December. Whilst the
size of this variant-driven wave in terms of infections and
cases is uncertain, we do know that it will produce a wave
of hospitalisations and deaths as well.”
What part
can antiviral treatments play?
“One thing to
remember is that the current variants of COVID-19 are
similar in severity to the original variant that was
circulating in 2020, the key difference is that we now have
vaccinations that substantially reduce the likelihood of
hospitalisation and death, and we have improved therapeutics
including antivirals. Antivirals have been associated with a
significant decrease in the risks of hospitalisation or
death, especially in higher risk groups, of around 80%.
Another way of saying that is that they can make it 5 times
less likely that you will be hospitalised or
die.
“Effective use of antivirals has the potential
to reduce the load on hospitals and the number of
hospitalisations and deaths substantially. The biggest issue
is that in order for them to work, they need to be used
early on in the infections. This means that people need to
be detecting that they have COVID-19 as early as possible in
their infection, and then be able to get a prescription, and
get it filled, promptly.
“Although Rapid Antigen
Tests are an incredible technology, giving people the
ability to test themselves at home and to get a result back
quickly, we know there is a lag at the beginning of the
infection before they will detect a case. Data from NZ shows
that this lag means the majority of people will not test
positive until day 2 or 3 of symptoms, and some will take 5
or 6 days.
“This can be a problem as antivirals need
to be started within 5-7 days of symptom onset, and it can
take some time to get a prescription especially over
weekends or public holidays. Because of this, it would be
good to see more availability of PCR testing for those
people at high risk (those eligible for antivirals) who have
COVID-19 symptoms but have tested negative on RATs. This
would have the added benefit that it would also improve our
variant surveillance in the community – right now, we do
not have enough PCR testing going on to get a good picture
of the variant landscape.
“Additionally, with the
expected wave of infections lining up with the Christmas
period, it will be difficult to find a GP or pharmacy that
can prescribe antivirals, and to find a pharmacy that is
open and can fill the prescription. For those at high risk
(those eligible for antivirals) more availability of advance
prescriptions would ease the load during the Christmas
break.”
Conflict of interest statement: “Dr
Harvey’s employer receives funding from the DPMC for her
to provide modelling and analysis to government officials on
Aotearoa’s COVID response, and from the NZ Health Research
Council for a project on modelling and equity for COVID-19
in Aotearoa.”
Associate Professor Dianne
Sika-Paotonu, Immunologist, Associate Dean (Pacific), Head
of University of Otago Wellington Pacific Office, and
Associate Professor, Dean’s Department, University of
Otago Wellington, comments:
What are antiviral
treatments?
“Antiviral medicines are used to treat
people who’ve already been infected with a virus, such as
the SARS-CoV-2 virus, which causes Covid-19. Steps to widen
the eligibility criteria and broaden
availability for antiviral medications to treat Covid-19
have been announced
previously in Aotearoa New Zealand. There had
been significant global demand for antiviral medications,
and countries had been challenged in trying to get access to
some medications.”
What do antivirals do, and who
needs them?
“In general, antivirals reduce and limit
the severity of symptoms that someone might experience with
a viral infection, lessen the duration of the viral illness
and shorten the length of time that someone stays unwell
for, and reduces viral transmission.
“Antivirals
need to reach those who require them, at the time they need
them, in order to prevent severe illness and hospitalisation
– and try to help our hospitals and support systems,
primary and community care right now.”
How available
are Covid-19 antivirals in NZ?
“For antivirals to be
effective, people with Covid-19 need to get access to them
quickly and the sooner the better – within five days of
symptoms showing. Accessibility and availability issues will
limit and hamper the usefulness of antivirals to treat
Covid-19.”
What is the outlook from here, with
reinfections on the rise?
“The newer variants and
subvariants of the SARS-CoV-2 virus have caused problems
with higher transmissibility, with Covid-19 reinfections
remaining problematic.
“The Covid-19 pandemic has
continued to exacerbate pre-existing inequities in health
for vulnerable communities, with inequitable impact recently
demonstrated through the disproportionate representation of
Covid-19 associated deaths for Māori and Pacific peoples
– sympathies and condolences are respectfully extended to
all family, whānau, kāinga, aiga and friends impacted and
affected.
“It is important to remember, however,
that antivirals are not a substitute for Covid-19 vaccines
and boosters – these are still much needed at this time to
work alongside simple public health measures that include
vaccines and boosters, masks, isolating when sick, proper
ventilation and other public health measures, remain
important steps to help protect against the severe impact of
Covid-19, against reinfection, and also other illnesses
still circulating at this time.
“Vigilance is still
needed – especially for our vulnerable
communities.”
No conflicts of interest
declared.
© Scoop Media




















Discussion about this post